An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Getting a flu shot may not only protect you from getting sick, it might also prevent heart disease.
A new Lancet Series explores the latest developments in the diagnosis, treatment and biology of cardiac arrhythmias, ahead of the American Heart Association’s annual meeting taking place this year on Nov 3–7 in Los Angeles, CA, USA.
Researchers at the National Heart Centre Singapore (NHCS) have successfully created a human heart cell model of arrhythmogenic right ventricular cardiomyopathy (ARVC), an inherited heart muscle disorder which puts one at high risk of developing life-threatening arrhythmias and sudden cardiac death.
Micro Interventional Devices, Inc., an emerging cardiovascular medical device company, announced today that the first patient has been treated using its self-sealing, cardiac access and closure technology, Permaseal. The patient is the first to be enrolled in the company's STASIS clinical trial that has commenced in Europe.
An analysis of the association of alcohol consumption with the development of atrial fibrillation (AF) among subjects with coronary heart disease, stroke, diabetes, or other manifestations of cardiovascular disease (CVD) was based on subjects in two large antihypertensive drug treatment trials.
Working with individuals with traumatic brain injury (TBI) every day, I see the debilitating effects and long-term struggles firsthand.
The mortality reduction with ticagrelor versus clopidogrel is due to fewer deaths from cardiovascular, bleeding, and infection complications, say researchers.
The U.S. Food and Drug Administration today approved a heart defibrillator that helps to restore regular heart rhythms with leads that can be implanted just under the skin (subcutaneously) instead of connected directly into the heart.
Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for ELIQUIS (apixaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).
A team of cardiologists from the Montreal Heart Institute (MHI) specializing in cardiac arrhythmias has used for the very first time in Canada, a technology developed in Montreal to treat a patient with atrial fibrillation. Recently licenced by Health Canada, this sophisticated device is a balloon inserted by catheter that uses extreme cold to burn malfunctioning heart tissue.
A novel blood thinner recently approved by the FDA, dabigatran (Pradaxa), has been rapidly adopted into clinical practice, yet thus far has had little impact on improving treatment rates for atrial fibrillation.
Bristol-Myers Squibb and Pfizer Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending that ELIQUIS (apixaban) be granted approval for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) and one or more risk factors for stroke.
Sentara Heart Hospital is leading the way in an innovative Atrial Fibrillation (AF) procedure for what is typically the most difficult to treat or persistent, forms of AF. This past week, surgeons and cardiologists at Sentara Heart Hospital were the first in the world to begin performing surgeries in the Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study (Staged DEEP) feasibility trial.
Avanir Pharmaceuticals, Inc. today announced the enrollment of the first patient in study AVR-131. The study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.
Atrial fibrillation is a common complication of cardiac surgery, occurring in 10 percent to 40 percent of patients. Recent studies show it to be associated with poorer health following surgery and poorer long-term survival. Furthermore, development of atrial fibrillation after cardiac surgery leads to average additional health care costs of $15,000 to $20,000.
Janssen Research & Development, LLC, announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for ZYTIGA (abiraterone acetate) administered in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.
The analysis was conducted using five editions of the EHRA White Book, which is produced by the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC).
The 2012 expert consensus statement on catheter and surgical ablation of atrial fibrillation was developed by the Heart Rhythm Society (HRS), the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC), and the European Cardiac Arrhythmia Society (ECAS) and published in their respective journals: Heart Rhythm, EP Europace and the Journal of Interventional Cardiovascular Electrophysiology (JICE).
Patients with irregular heartbeats (arrhythmia) are difficult to image with CT. Addressing this challenge, Carnegie Hill Radiology in New York installed the Aquilion PRIME 160 series from Toshiba America Medical Systems, Inc., featuring SURECardio Prospective software that automatically adjusts for irregular heartbeats, providing quicker, more accurate exams.
Lifelong anticoagulation is necessary for the prevention of stroke in patients with rhythm disturbances and with mechanical valves. Patients who have a coronary stent implanted also need the antiplatelet drugs aspirin and clopidogrel to prevent the rare but lethal complication of stent thrombosis.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.